Invivyd, Inc. (IVVD) Stock
IVVD Key Statistics
About Invivyd, Inc.
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
CEO: William E. Duke Jr.. Company website
IVVD — Frequently Asked Questions
What is the IVVD stock price today?
Invivyd, Inc. (IVVD) trades at $0.75, down 21.03% on the day, as of Sep 20, 2026 14:59 UTC.
What is Invivyd, Inc.'s market cap?
Invivyd, Inc. has a market capitalisation of $100.09M, calculated from the live IVVD share price and shares outstanding.
What is the P/E ratio of IVVD?
IVVD has no meaningful price-to-earnings ratio: Invivyd, Inc. lost $0.38 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Invivyd, Inc. make?
Invivyd, Inc. generated revenue of $53.43M over the trailing twelve months, which puts the stock at 1.87 times sales.
What is the 52-week range for IVVD?
IVVD has traded between $0.53 and $2.04 over the past 52 weeks, and the last price is 63.0% below that high.
Is Invivyd, Inc. profitable?
No. Invivyd, Inc. is loss-making, with a net margin of -98.25% over the trailing twelve months.
What is the analyst price target for IVVD?
Wall Street analysts rate IVVD Buy, with an average price target of $9.50, 1,159.8% above the current price.
What sector is Invivyd, Inc. in?
Invivyd, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US .
Who is the CEO of Invivyd, Inc.?
William E. Duke Jr. is the chief executive of Invivyd, Inc., which employs 99 people.
Where can I track IVVD in real time?
QFI Terminal shows IVVD with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See IVVD live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open IVVD in Terminal See plans